{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T02:31:33Z","timestamp":1788489093330,"version":"build-2803163510"},"reference-count":52,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T00:00:00Z","timestamp":1642982400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Halozyme Inc."}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Subcutaneous (SC) administration of rituximab provides an opportunity for reduced patient treatment burden and increased healthcare efficiencies as an alternative to intravenous (IV) rituximab. There is minimal evidence comparing costs associated with SC and IV rituximab in a US setting. This research assessed the impact of transitioning patients from IV to SC rituximab for treatment of non-Hodgkin\u2019s lymphoma (NHL) from the US payer, provider, and patient perspective. We developed a model to estimate cost differences for transitioning 20% of a patient cohort from IV to SC rituximab. We included patients with incident diffuse large B-cell lymphoma, incident and recurrent follicular lymphoma, and incident and recurrent chronic lymphocytic leukemia. In the model, each patient received the same number of doses and that there was no difference in discontinuation between cohorts due to non-inferior efficacy and a similar safety profile. Model inputs were collected from published literature and publicly available data. Scenario analyses tested the impact of availability of low-cost biosimilars. In the base case (1,000,000 covered lives), we estimated a total of 157 patients, with 769 total drug administrations. A transition of 20% of patients from IV to SC was projected to generate $153,000 in payer savings, increase provider capacity by 270 hours, and free 470 hours of patient time. Scenario analyses suggest SC administration will be cost saving for payers even with a market where biosimilars approach 50% market share. A 20% transition to SC rituximab in a single cohort of patients has the potential to generate significant US health system value in the form of payer savings, increased practice capacity, and patient time.<\/jats:p>","DOI":"10.1371\/journal.pone.0261336","type":"journal-article","created":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T18:27:01Z","timestamp":1643048821000},"page":"e0261336","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":34,"title":["Assessing the transition from intravenous to subcutaneous delivery of rituximab: Benefits for payers, health care professionals, and patients with lymphoma"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7298-1341","authenticated-orcid":true,"given":"Michael J.","family":"Harvey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob N.","family":"Beverage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita J.","family":"Chawla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,1,24]]},"reference":[{"issue":"5","key":"pone.0261336.ref001","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40259-018-0295-0","article-title":"Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities","volume":"32","author":"B Bittner","year":"2018","journal-title":"BioDrugs"},{"key":"pone.0261336.ref002","article-title":"Intravenous versus Subcutaneous Drug Administration. Which Do Patients Prefer? A Systematic Review","author":"KL Stoner","year":"2014","journal-title":"Patient"},{"issue":"3","key":"pone.0261336.ref003","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/NAN.0b013e31824d2271","article-title":"Subcutaneous drug delivery: a route to increased safety, patient satisfaction, and reduced costs","volume":"35","author":"SS Dychter","year":"2012","journal-title":"J Infus Nurs"},{"issue":"28","key":"pone.0261336.ref004","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.2217\/fon-2019-0368","article-title":"Humanistic and economic impact of subcutaneous versus intravenous administration of oncology biologics","volume":"15","author":"KC Anderson","year":"2019","journal-title":"Future Oncol"},{"key":"pone.0261336.ref005","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jconrel.2018.08.001","article-title":"Subcutaneous delivery of monoclonal antibodies: How do we get there","volume":"286","author":"M Viola","year":"2018","journal-title":"J Control Release"},{"issue":"5","key":"pone.0261336.ref006","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.xphs.2018.01.007","article-title":"Challenges and Opportunities for the Subcutaneous Delivery of Therapeutic Proteins","volume":"107","author":"MR Turner","year":"2018","journal-title":"J Pharm Sci"},{"issue":"4","key":"pone.0261336.ref007","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1093\/annonc\/mdw685","article-title":"Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomized, open-label, crossover study (PrefMab).","volume":"28","author":"M Rummel","year":"2017","journal-title":"Annals of Oncology"},{"issue":"4","key":"pone.0261336.ref008","article-title":"Accelerating the delivery of cancer care at home during the Covid-19 pandemic.","volume":"1","author":"AI Laughlin","year":"2020","journal-title":"NEJM Catalyst Innovations in Care Delivery."},{"issue":"1","key":"pone.0261336.ref009","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1080\/10717544.2018.1551442","article-title":"ENHANZE(\u00ae) drug delivery technology: a novel approach to subcutaneous administration using recombinant human hyaluronidase PH20","volume":"26","author":"KW Locke","year":"2019","journal-title":"Drug delivery"},{"issue":"10","key":"pone.0261336.ref010","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","article-title":"Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience","volume":"34","author":"G Salles","year":"2017","journal-title":"Adv Ther"},{"issue":"10","key":"pone.0261336.ref011","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1007\/s12325-017-0610-z","article-title":"Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development.","volume":"34","author":"A Davies","year":"2017","journal-title":"Adv Ther"},{"key":"pone.0261336.ref012","unstructured":"U.S. Food and Drug Administration. Prescribing information for Rituxan Hycela (rituximab and hyaluronidase human) injection. 2020."},{"issue":"6","key":"pone.0261336.ref013","doi-asserted-by":"crossref","first-page":"e0157957","DOI":"10.1371\/journal.pone.0157957","article-title":"Time Savings with Rituximab Subcutaneous Injection versus Rituximab Intravenous Infusion: A Time and Motion Study in Eight Countries","volume":"11","author":"E De Cock","year":"2016","journal-title":"PLOS ONE"},{"key":"pone.0261336.ref014","doi-asserted-by":"crossref","first-page":"319","DOI":"10.2147\/CMAR.S69145","article-title":"Critical appraisal of rituximab in the maintenance treatment of advanced follicular lymphoma","volume":"7","author":"D Aguiar-Bujanda","year":"2015","journal-title":"Cancer management and research"},{"key":"pone.0261336.ref015","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/j.jval.2018.04.137","article-title":"Budget Impact of the Introduction of Subcutaneous Rituximab to U.S. Health Plans.","volume":"21","author":"RN Hansen","year":"2018","journal-title":"Value in Health"},{"issue":"Supplement 1","key":"pone.0261336.ref016","doi-asserted-by":"crossref","first-page":"4776","DOI":"10.1182\/blood-2018-99-113283","article-title":"Subcutaneous versus intravenous rituximab in non-Hodgkin lymphoma treated with R-CHOP: economic modeling for the US","volume":"132","author":"A McBride","year":"2018","journal-title":"Blood"},{"key":"pone.0261336.ref017","first-page":"1","article-title":"The challenge of sustainability in healthcare systems: economic and organizational impact of subcutaneous formulations for rituximab and trastuzumab in onco-hematology","author":"M Altini","year":"2020","journal-title":"Expert Review of Pharmacoeconomics & Outcomes Research."},{"issue":"10","key":"pone.0261336.ref018","first-page":"862","article-title":"Medico-economic benefits of subcutaneous formulations of trastuzumab and rituximab in day hospitalisation (SCuBA Study)","volume":"105","author":"M Favier","year":"2018","journal-title":"Bull Cancer"},{"issue":"1","key":"pone.0261336.ref019","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00277-017-3147-y","article-title":"SMABcare study: subcutaneous monoclonal antibody in cancer care: cost-consequence analysis of subcutaneous rituximab in patients with follicular lymphoma","volume":"97","author":"E Fargier","year":"2018","journal-title":"Annals of Hematology"},{"issue":"5","key":"pone.0261336.ref020","doi-asserted-by":"crossref","first-page":"300","DOI":"10.3747\/co.25.4231","article-title":"Evaluation of subcutaneous rituximab administration on Canadian systemic therapy suites","volume":"25","author":"DA Stewart","year":"2018","journal-title":"Curr Oncol"},{"issue":"2","key":"pone.0261336.ref021","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3747\/co.27.6041","article-title":"Update on the subcutaneous administration of rituximab in Canadian cancer centres","volume":"27","author":"D Stewart","year":"2020","journal-title":"Current Oncology"},{"key":"pone.0261336.ref022","first-page":"227","article-title":"Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin\u2019s lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey","volume":"8","author":"C Ponzetti","year":"2016","journal-title":"ClinicoEconomics and outcomes research: CEOR"},{"issue":"7","key":"pone.0261336.ref023","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3111\/13696998.2014.914033","article-title":"Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom","volume":"17","author":"S Rule","year":"2014","journal-title":"Journal of medical economics"},{"issue":"6","key":"pone.0261336.ref024","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.clinthera.2017.05.342","article-title":"Microcosting study of rituximab subcutaneous injection versus intravenous infusion","volume":"39","author":"J Mihajlovi\u0107","year":"2017","journal-title":"Clinical Therapeutics"},{"issue":"11","key":"pone.0261336.ref025","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.3324\/haematol.2017.173583","article-title":"Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study","volume":"102","author":"P Lugtenburg","year":"2017","journal-title":"Haematologica"},{"issue":"8","key":"pone.0261336.ref026","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1097\/CAD.0000000000000648","article-title":"Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands.","volume":"29","author":"MG Franken","year":"2018","journal-title":"Anti-cancer drugs"},{"issue":"6","key":"pone.0261336.ref027","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1016\/S2352-3026(17)30078-9","article-title":"Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial.","volume":"4","author":"A Davies","year":"2017","journal-title":"The Lancet Haematology"},{"issue":"3","key":"pone.0261336.ref028","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S1470-2045(14)70005-1","article-title":"Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study","volume":"15","author":"A Davies","year":"2014","journal-title":"The lancet oncology"},{"issue":"6","key":"pone.0261336.ref029","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1038\/bjc.2013.371","article-title":"Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase","volume":"109","author":"O Shpilberg","year":"2013","journal-title":"British journal of cancer"},{"key":"pone.0261336.ref030","article-title":"Projected Age Groups and Sex Composition of the Population: Main Projections Series for the United States, 2017\u20132060","author":"U.S. Census Bureau","year":"2017"},{"issue":"24","key":"pone.0261336.ref031","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/jnci\/94.24.1883","article-title":"Role of Body Surface Area in Dosing of Investigational Anticancer Agents in Adults, 1991\u20132001. JNCI","volume":"94","author":"SD Baker","year":"2002","journal-title":"Journal of the National Cancer Institute"},{"key":"pone.0261336.ref032","unstructured":"Amgen Inc. Amgen 2020 Biosimilar Trends Report 2020 [cited 2021 Feb]. Available from: https:\/\/www.amgenbiosimilars.com\/-\/media\/Themes\/Amgen\/amgenbiosimilars-com\/Amgenbiosimilars-com\/pdf\/USA-CBU-80723-2020-Amgen-Biosimilar-Trends-Report.pdf."},{"key":"pone.0261336.ref033","article-title":"SEER Cancer Statistics Review, 1975\u20132016","author":"N Howlader","year":"2019"},{"key":"pone.0261336.ref034","author":"RA Young","journal-title":"A Time-Motion Study of Primary Care Physicians\u2019 Work in the Electronic Health Record Era"},{"issue":"1","key":"pone.0261336.ref035","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1186\/1472-6963-12-370","article-title":"Patient and work flow and costs associated with staff time and facility usage at a comprehensive cancer centre in Quebec, Canada\u2013a time and motion study","volume":"12","author":"GA Shinder","year":"2012","journal-title":"BMC Health Services Research"},{"key":"pone.0261336.ref036","unstructured":"U.S. Food and Drug Administration. Prescribing information for Rituxan (rituximab). 2010."},{"issue":"4","key":"pone.0261336.ref037","doi-asserted-by":"crossref","DOI":"10.1097\/00129804-200407000-00008","article-title":"A Nursing Process Model: Quantifying Infusion Therapy Resource Consumption","volume":"27","author":"CA Pierce","year":"2004","journal-title":"Journal of Infusion Nursing"},{"key":"pone.0261336.ref038","unstructured":"Centers for Medicare & Medicaid Services. 2021 ASP Drug Pricing Files 2021 [cited 2021 February]. Available from: https:\/\/www.cms.gov\/medicare\/medicare-part-b-drug-average-sales-price\/2020-asp-drug-pricing-files."},{"key":"pone.0261336.ref039","unstructured":"Centers for Medicare & Medicaid Services. 2021 Medicare Physician Fee Schedule 2021 [cited 2021 February]. Available from: https:\/\/www.cms.gov\/apps\/physician-fee-schedule\/overview.aspx."},{"key":"pone.0261336.ref040","unstructured":"IBM Watson Health. Micromedex\u00ae (electronic version) Greenwood Village, Colorado, USA [cited 2020 December 7]. Available from: https:\/\/www.micromedexsolutions.com\/."},{"key":"pone.0261336.ref041","unstructured":"MedEx Supply. [cited 2020 February]. Available from: https:\/\/www.medexsupply.com\/."},{"key":"pone.0261336.ref042","unstructured":"Mountainside Medical Equipment. Mountainside Medical Equipment Wholesale Medical Supplies & Equipment [cited 2020 February]. Available from: https:\/\/www.mountainside-medical.com\/."},{"key":"pone.0261336.ref043","unstructured":"USA Medical and Surgical Supplies. [cited 2020 February]. Available from: https:\/\/www.usamedicalsurgical.com\/."},{"key":"pone.0261336.ref044","unstructured":"Westend Medical. [cited 2020 February]. Available from: https:\/\/westendmedicalsupplies.com\/."},{"issue":"6","key":"pone.0261336.ref045","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1310\/hpj5106-452","article-title":"Enhancing the Budget Impact Model for Institutional Use: A Tool with Practical Applications for the Hospital Oncology Pharmacy.","volume":"51","author":"LM Hess","year":"2016","journal-title":"Hospital Pharmacy"},{"key":"pone.0261336.ref046","unstructured":"U.S. Bureau of Labor Statistics. 2018 Standard Occupational Classification 2020 [cited 2020 February]. Available from: https:\/\/www.bls.gov\/soc\/2018\/."},{"issue":"4","key":"pone.0261336.ref047","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1080\/13696998.2017.1285779","article-title":"Costs of providing infusion therapy for patients with inflammatory bowel disease in a hospital-based infusion center setting","volume":"20","author":"A Afzali","year":"2017","journal-title":"J Med Econ"},{"issue":"4","key":"pone.0261336.ref048","first-page":"312","article-title":"Essentials for improving service quality in cancer care","volume":"4","author":"LL Berry","year":"2016","journal-title":"Healthcare (Amsterdam, Netherlands)."},{"key":"pone.0261336.ref049","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.jconrel.2020.02.036","article-title":"Accelerating the development of novel technologies and tools for the subcutaneous delivery of biotherapeutics","volume":"321","author":"DS Collins","year":"2020","journal-title":"Journal of Controlled Release"},{"key":"pone.0261336.ref050","article-title":"Prescribing information for Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) injection","author":"U.S. Food and Drug Administration.","year":"2020"},{"key":"pone.0261336.ref051","unstructured":"U.S. Food and Drug Administration. Prescribing information for Darzalex Faspro (daratumumab and hyaluronidase\u2014fihj) injection. 2020."},{"issue":"1","key":"pone.0261336.ref052","first-page":"53","article-title":"Delivering High-Quality Cancer Care: The Critical Role of Quality Measurement.","volume":"2","author":"T Spinks","year":"2014","journal-title":"Healthcare (Amsterdam, Netherlands)."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0261336","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T18:27:34Z","timestamp":1643048854000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0261336"}},"subtitle":[],"editor":[{"given":"Ahmet Emre","family":"E\u015fkazan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,1,24]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0261336","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,24]]}}}